Ticker League

Alnylam Pharmaceuticals (ALNY) Free Cash Flow Bridge

Pinpoint what moved Alnylam Pharmaceuticals's free cash flow from TTM through Q1 2025 to TTM through Q1 2026 — operating cash flow shifts and capex changes, each driver sized in dollars.

TTM

FCF YoY

+950.75%

OCF YoY

+1,680.32%

Capex YoY

+136.37%

FCF Conversion Δ

-77.1 pp

Free cash flow bridge for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Free cash flow: $716.72M

FCF bridge breakdown for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Free Cash Flow−$75.39M
  • Operating Cash Flow$758.01M
  • Capital Expenditure−$41.29M
  • Free Cash Flow$641.34M
Identity check: drivers reconcile to ΔNI within $0.00
Want to see how cash flow is built up?Cash Flow Waterfall

Frequently asked questions

Data & methodology

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation